For example, previous studies have divided CCA into four subtypes based on genomic mutations and revealed the molecular characteristics of CCA by integrating multi-omics data 6, suggesting that activating fusions of FGFR and mutations of IDH1/2 can be used as new therapeutic targets. The gene discussed is IDH1; the disease is cholangiocarcinoma.